Skip to main content

Table 3 Most common adverse events (Grade ≥ 3) during induction

From: Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial

AE

Grade ≥ 3

Haematological adverse events

 Neutropenia

100% (41/41)

 Anaemia

100% (41/41)

 Thrombocytopenia

100% (41/41)

Non-haematological adverse events

 Febrile neutropenia

92.7% (38/41)

 Pneumonia

46.3% (19/41)

 Upper respiratory infection

31.7% (13/41)

 Skin and soft tissue infection

14.6% (13/41)

 Bacteremia

7.3% (3/41)

 Intestinal infection

4.9% (2/41)